Thursday, November 02, 2017 8:53:55 PM
Thank all of you experts for helping us. You are the best.
HEALTHY LIVING
NATURAL CURES
DISEASE PREVENTION
DIET AND EXERCISE
CONTACT US
ABOUT US
Parkinson’s Breakthrough!
By Adam - October 12, 2017 180 0
SHARE Facebook Twitter
Scientists in South Korea and Singapore are overturning three decades’ worth of knowledge about Parkinson’s and what causes it.
Up until now, scientists have thought that the cause of the lack of voluntary movement (which is one of the biggest characteristics of Parkinson’s) is low levels of dopamine. However, this no longer seems to be the case.
The basal ganglia regulates the body’s voluntary movement. This region of the brain basically shifts between getting instructions to allow movement, and getting instructions to suppress movement.
Well, researchers Daesoo Kim (South Korea) and George Augustine (Singapore) made use of the cutting-edge technology optogenetics to intensify the motor suppression instructions given to rats’ brains.
As Medical News Today states:
“However, they found that this made ventrolateral thalamic neurons – which are involved in motor control – hyperactive.
This hyperactivity seemed to cause muscular rigidity and contractions in the rodents – symptoms similar to the hallmark motor symptoms in Parkinson’s disease.
As the authors explain, this is the phenomenon called “rebound firing,” which seems to be triggered by intensifying inhibitory basal ganglia inputs.
Prof. Kim and team tested the role of this phenomenon by genetically engineering mice to lack dopamine and inhibiting rebound firing to see what effects it would have on Parkinson’s disease motor symptoms.
Rebound firing was inhibited by genetically interfering to reduce the number of ventrolateral thalamic neurons.”
SHOCKINGLY, THE MICE WITH EXTREMELY LOW LEVELS OF DOPAMINE – BUT NO REBOUND FIRING – SHOWED NO SYMPTOMS OF PARKINSON’S.
According to Kim and Augustine:
“In a low dopamine state,” the authors say, “the number of [ventrolateral thalamic] neurons showing post-inhibitory firing increases, while reducing the number of active [ventrolateral thalamic] neurons [by inhibiting basal ganglia] input, effectively prevents Parkinson disease-like motor symptoms.”
“Thus, [basal ganglia] inhibitory input generates excitatory motor signals in the thalamus and, in excess, promotes PD-like [Parkinson’s disease-like] motor abnormalities,” they conclude.
“THIS STUDY,” SAYS PROF. DAESOO KIM, AS HE COMMENTS ON THE SIGNIFICANCE OF THE FINDINGS, “OVERTURNS THREE DECADES OF CONSENSUS ON THE PROVENANCE OF PARKINSONIAN SYMPTOMS.”
First study author Dr. Jeongjin Kim says, “The therapeutic implications of this study for the treatment of Parkinsonian symptoms are profound. It may soon become possible to remedy movement disorders without using L-Dopa, a precursor to dopamine.”
These findings offer significant breakthroughs in the understanding of Parkinson’s disease and the way it comes to form in the body.
Through this study, researchers now have a far greater understanding of how the brain typically controls the body’s movement, and how Parkinson’s disease affects this control.
Recent AVXL News
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM